Efficacy of Lentinula Edodes-Derived Supplement (AHCC®) in Promoting Negativity of Persistent HPV Infection
NCT ID: NCT06752083
Last Updated: 2024-12-30
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
219 participants
OBSERVATIONAL
2023-01-02
2024-12-15
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Unvaccinated with AHCC® Supplement
Participants receiving 3 capsules of AHCC® daily for 4-6 months. These participants were unvaccinated prior to the study and were treated with the dietary supplement to evaluate its impact on HPV negativity.
AHCC® (Active Hexose Correlated Compound)
3 capsules of AHCC® daily for 4-6 months to support immune modulation and promote HPV negativity.
Vaccinated with AHCC® Supplement
Participants receiving both the Gardasil 9® vaccine and 3 capsules of AHCC® daily for 6 months. This group evaluates the combined impact of vaccination and dietary supplementation on HPV negativity.
AHCC® (Active Hexose Correlated Compound)
3 capsules of AHCC® daily for 4-6 months to support immune modulation and promote HPV negativity.
Gardasil 9®
Administration of the nonavalent HPV vaccine to provide protection against high-risk HPV genotypes.
Vaccinated Only
Participants receiving only the Gardasil 9® vaccine without any AHCC® supplementation. This group serves as a comparator to evaluate the effects of the dietary supplement.
Gardasil 9®
Administration of the nonavalent HPV vaccine to provide protection against high-risk HPV genotypes.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
AHCC® (Active Hexose Correlated Compound)
3 capsules of AHCC® daily for 4-6 months to support immune modulation and promote HPV negativity.
Gardasil 9®
Administration of the nonavalent HPV vaccine to provide protection against high-risk HPV genotypes.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Persistent HPV infection for at least 6 continuous months, confirmed by DNA-HPV testing.
* No prior treatment for cervical lesions via conization.
* No prior HPV vaccination
Exclusion Criteria
* Immunocompromised status, including known HIV infection.
* Severe or high-grade cervical lesions.
* Known allergy or hypersensitivity to AHCC® or vaccine components.
18 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Università degli Studi dell'Insubria
OTHER
Liaquat University of Medical & Health Sciences
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Dr. Amjad Khan
Professor of Clinical Biochemistry and Experimental Medicine
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Insubria
Varese, , Italy
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Gau VL, Benninger MS. Potential Role for Active Hexose Correlated Compound (AHCC) in Treatment of Recurrent Respiratory Papillomatosis. J Voice. 2022 Jul;36(4):441-442. doi: 10.1016/j.jvoice.2022.05.004. Epub 2022 Jun 27. No abstract available.
Smith JA, Mathew L, Gaikwad A, Rech B, Burney MN, Faro JP, Lucci JA 3rd, Bai Y, Olsen RJ, Byrd TT. From Bench to Bedside: Evaluation of AHCC Supplementation to Modulate the Host Immunity to Clear High-Risk Human Papillomavirus Infections. Front Oncol. 2019 Mar 20;9:173. doi: 10.3389/fonc.2019.00173. eCollection 2019.
Smith JA, Gaikwad AA, Mathew L, Rech B, Faro JP, Lucci JA 3rd, Bai Y, Olsen RJ, Byrd TT. AHCC(R) Supplementation to Support Immune Function to Clear Persistent Human Papillomavirus Infections. Front Oncol. 2022 Jun 22;12:881902. doi: 10.3389/fonc.2022.881902. eCollection 2022.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
117_22.112024_Papion®
Identifier Type: -
Identifier Source: org_study_id